Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10815220 | Cellular Signalling | 2016 | 36 Pages |
Abstract
- Circulating AVP is elevated in HF patients, which is associated with increased morbidity and mortality.
- Chronic AVP signaling via V1AR and V2R leads to increased cardiac hypertrophy and renal water reabsorption, respectively.
- V2R-selective antagonists reduce water reabsorption, but increase AVP levels and mortality in HF patients.
- Cardiac V1AR expression is increased two-fold in HF patients, results replicated in both small and large animal models of HF.
- Chronic V1AR signaling promotes cardiac remodeling, βAR desensitization and contractile dysfunction.
- These effects are reversed by V1AR blockade, providing rationale for targeting this system as a therapeutic approach for HF.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Melissa A. Wasilewski, Valerie D. Myers, Fabio A. Recchia, Arthur M. Feldman, Douglas G. Tilley,